secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001437749-24-009695
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Health sells BioReference clinical diagnostics business to LabCorp for ~$237.5M
--------------------------------------------------------------------------------

- Asset Purchase Agreement with LabCorp for $237.5M cash, excluding oncology/urology and NY/NJ operations.
- Transaction includes transfer of certain BioReference employees; no financing condition required.
- Closing subject to HSR clearance and customary conditions; 180-day outside date with potential extensions.
- Termination fee payable by LabCorp in certain circumstances if regulatory clearance fails.
- OPKO retains nationwide oncology/urology and all NY/NJ operations post-closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000143774924009695/0001437749-24-009695-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000143774924009695/opk20240311_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-009695

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer